Amendment to CSSB 6, Section 1.45, page 60, line 16 (5) development of protocols for use pyschotropic medications for foster children based on the recommendations and best practices manual developed by an ad hoc work group consisting of experts from the fields of pharmacy, psychiatry, pediatrics, family practice, and internal medicine and staff from the commission. Is amended to read: No ad hoc working group, or other group or team set up to develop protocols for the use of psychotropic medications in foster children shall receive donations, gifts, or other funding from pharmaceutical companies or other groups who could be understood to have a financial stake in the use of such medications. No member of any team for developing psychotropic drug protocols shall have: (a) a history of employment by a pharmaceutical company in the past three years; (b) a financial interest in a pharmaceutical company; (c) or shall have conducted studies, clinical trials, or other activities funded by a pharmaceutical company for at least three years.